SEARCH

SEARCH BY CITATION

References

  • Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1S324.
  • Auclair A, Drouin C, Cotecchia S, Glowinski J, Tassin JP (2004). 5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants. Eur J Neurosci 20: 30733084.
  • Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1988). Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149: 159163.
  • Bossong MG, Van Dijk JP, Niesink RJ (2005). Methylone and mCPP, two new drugs of abuse? Addict Biol 10: 321323.
  • Brunt TM, Poortman A, Niesink RJ, Van den Brink W (2011). Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 25: 15431547.
  • Camarasa J, García-Ratés S, Pubill D, Escubedo E (2009). The involvement of nicotinic receptor subtypes in the locomotor activity and analgesia induced by methamphetamine in mice. Behav Pharmacol 20: 623630.
  • Chad RM, Copeland CR (2010). Characterization of three methcathinone analogs: 4-methylmethcathinone, methylone and bk-MBDB. Microgram J 7: 4249.
  • Chipana C, García-Ratés S, Camarasa J, Pubill D, Escubedo E (2008a). Different oxidative profile and nicotinic receptor interaction of amphetamine and 3,4-methylenedioxy-methamphetamine. Neurochem Int 52: 401410.
  • Chipana C, Torres I, Camarasa J, Pubill D, Escubedo E (2008b). Memantine protects against amphetamine derivatives-induced neurotoxic damage in rodents. Neuropharmacology 54: 12541263.
  • Clark MS, Sexton TJ, McClain M, Root D, Kohen R, Neumaier JF (2002). Overexpression of 5-HT1B receptor in dorsal raphe nucleus using herpes simplex virus gene transfer increases anxiety behaviour after inescapable stress. J Neurosci 22: 45504562.
  • Cozzi NV, Sievert MK, Shulgin AT, Jacobill P, Rhuolo AE (1999). Inhibition of plasma membrane monoamine transporters by betaketoamphetamines. Eur J Pharmacol 381: 6369.
  • Drug Enforcement Administration, Department of Justice (2011). Schedules of controlled substances: temporary placement of three synthetic cathinones in Schedule I. Final order. Fed Regist 76: 6537165375.
  • Erritzoe D, Frokjaer VG, Holst KK, Christoffersen M, Johansen SS, Svarer C et al. (2011). In vivo imaging of cerebral serotonin transporter and serotonin(2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or ‘ecstasy’) and hallucinogen users. Arch Gen Psychiatr 68: 562576.
  • Escubedo E, Chipana C, Pérez-Sanchez M, Camarasa J, Pubill D (2005). Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha7 nicotinic receptors. J Pharmacol Exp Ther 315: 658667.
  • Fischer JF, Cho AK (1979). Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther 208: 203209.
  • Fleckenstein AE, Voltz TJ, Riddle EL, Gibb JW, Hanson GR (2007). New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47: 681698.
  • Foster JD, Cervinski MA, Gorentla BK, Vaughan RA (2006). Regulation of the dopamine transporter by phosphorylation. Handb Exp Pharmacol 175: 197214.
  • Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC et al. (2011). 4-methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339: 530536.
  • Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR et al. (2002). Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther 300: 10931100.
  • Hrometz SL, Brown AW, Nichols DE, Sprague JE (2004). 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B. Neurosci Lett 367: 5659.
  • Izawa J, Yamanashi K, Asakura T, Misu Y, Goshima Y (2006). Differential effects of methamphetamine and cocaine on behaviour and extracellular levels of dopamine and 3,4-dihydroxyphenylalanine in the nucleus accumbens of conscious rats. Eur J Pharmacol 549: 8490.
  • Jayanthi LD, Samuvel DJ, Blakely RD, Ramamoorthy S (2005). Evidence for biphasic effects of protein kinase C on serotonin transporter function, endocytosis, and phosphorylation. Mol Pharmacol 67: 20772087.
  • Jones DC, Lau SS, Monks TJ (2004). Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells. J Pharmacol Exp Ther 311: 298306.
  • Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F et al. (2011). Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats. Br J Pharmacol 164: 19491958.
  • Kot M, Daniel WA (2011). Cytochrome P450 is regulated by noradrenergic and serotonergic systems. Pharmacol Res 64: 371380.
  • Levi G, Raiteri M (1993). Carrier-mediated release of neurotransmitters. Trends Neurosci 16: 415419.
  • Leviel V (2001). The reverse transport of DA, what physiological significance? Neurochem Int 38: 83106.
  • Ljungberg T, Ungerstedt U (1985). A rapid and simple behavioural screening method for simultaneous assessment of limbic and striatal blocking effects of neuroleptic drugs. Pharmacol Biochem Behav 23: 479485.
  • Martínez-Clemente J, Escubedo E, Pubill D, Camarasa J (2012). Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 22: 231236.
  • McCreary AC, Bankson MG, Cunningham KA (1999). Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine (1A) and 5-hydroxytryptamine(1B/1D) receptors. J Pharmacol Exp Ther 290: 965973.
  • McElrath K, O'Neill C (2011). Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply. Int J Drug Policy 22: 120127.
  • McGrath JC, Drummond GB, McLachlan E, Kilkenny C, Wainwright CL (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 15731576.
  • Measham F, Moore K, Newcombe R, Welch Z (2010). Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perversity of prohibition. Drugs Alcohol Today 10: 1421.
  • Meng H, Cao J, Kang J, Ying X, Ji J, Reynolds W et al. (2012). Mephedrone, a new designer drug of abuse, produces acute hemodynamic effects in the rat. Toxicol Lett 208: 6268.
  • Motbey CP, Hunt GE, Bowen MT, Artiss S, McGregor IS (2012). Mephedrone (4-methylmethcathinone, ‘meow’): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict Biol 17: 409422.
  • Nagai F, Nonaka R, Satoh K, Kamimura SHK (2007). The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559: 132137.
  • Pubill D, Chipana C, Camins A, Pallas M, Camarasa J, Escubedo E (2005). Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol Appl Pharmacol 204: 5768.
  • Ramamoorthy S, Shippenberg TS, Jayanthi LD (2011). Regulation of monoamine transporters: role of transporter phosphorylation. Pharmacol Ther 129: 220238.
  • Regan L, Mitchelson M, MacDonald C (2011). Mephedrone toxicity in a Scottish emergency department. Emerg Med J 28: 10551058.
  • Rudnick G, Wall SC (1992). The molecular mechanism of ‘ecstasy’[3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A 89: 18171821.
  • Schifano F, Albanese A, Fergus S, Stair JL, DeLuca P, Corazza O et al. (2011). Mephedrone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues. Psychopharmacology 214: 593602.
  • Schuldiner S, Steiner-Mordoch S, Yelin R, Wall SC, Rudnik G (1993). Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol Pharmacol 44: 12271231.
  • Vardakou I, Pistos C, Spiliopoulou CH (2011). Drugs for youth via Internet and the example of mephedrone. Toxicol Lett 201: 191195.
  • Winstock A, Mitcheson L, Masden J (2010). Mephedrone: still available and twice the price. Lancet 376: 1537.
  • Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J (2011). Mephedrone: use, subjective effects and health risks. Addiction 106: 19911996.
  • Wood D, Dargan P (2010). ‘Mephedrone’ (4-methylmethcathinone): what is it, how commonly is it used and what are the risks associated with its use? Pharmacol Matters 3: 1114.
  • Yamamoto BK, Nash JF, Gudelsky GA (1995). Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J Pharmacol Exp Ther 273: 10631070.